共 50 条
- [31] Phase I dose-escalation study of the dual PI3K/mTORC1/2 inhibitor Gedatolisib (PF-05212384) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumoursANNALS OF ONCOLOGY, 2020, 31 : S487 - S487Colombo, I.Genta, S.Martorana, F.Guidi, M.Samartzis, E. S. P.Brandt, S.Gaggetta, S.Moser, L.Pascale, M. R.Terrot, T.Sessa, C.Stathis, A.
- [32] A phase 1 study of the PI3K/mTOR inhibitor PQR309 evaluating safety, pharmacokinetics (PK) and pharmacodynamics (PD) in patients (pts) with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Adjei, Alex A.Dy, Grace K.Zhao, YujieMa, Wen WeeOpyrchal, MateuszBakhribah, HatoonJacob, Sandra M.O'Hara, CorrieDozier, AskiaCmiljanovic, NatasaTodaro, BarbaraBrady, William E.Schmitz, DeboraDimitrijevic, Sasa
- [33] Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma ptsANNALS OF ONCOLOGY, 2022, 33 : S33 - S33Krebs, M. G.Tarruella, M. MajemForster, M.Peguero, J. A.Clay, T.Felip, E.Iams, W.Roxburgh, P.de Speville, B. DogerBajaj, P.Mueller, C.Triebel, F.
- [34] Interim analysis of a phase I study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor, in patients (pts) with relapsed or refractory (r/r) B-cell malignancies.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Phillips, Tycel JovelleForero-Torres, AndresSher, TaimurDiefenbach, Catherine S. MagidTalpaz, MosheScherle, Peggy A.Schaub, RichardZhou, LiPulini, JenniferLeopold, LanceSpear, Matthew A.Barr, Paul M.
- [35] A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Traynor, A. M.Kurzrock, R.Bailey, H. H.Attia, S.Scheffold, C.van Leeuwen, B.Wu, B.Falchook, G. S.Moulder, S. L.Wheler, J.
- [36] A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Moldovan, C.Soria, J.LoRusso, P.Guthrie, T.Song, C.Nguyen, L. T.Martini, J.Infante, J. R.Burris, H. A., III
- [37] A phase I study of a selective PI3Kδ inhibitor YY-20394 in patients with relapsed or refractory B-cell malignancies.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Qiu, LuguiQi, JunyuanSong, YuqinJiang, BoTu, MeifengPing, LingyanLi, ZengjunZhu, JunXu, YuanyuanBao, HanyingXu, Zusheng
- [38] Final results of a phase I study of idelalisib (GSE1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL.JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Brown, Jennifer R.Furman, Richard R.Flinn, IanCoutre, Steven E.Wagner-Johnston, Nina D.Kahl, Brad S.Spurgeon, Stephen Edward ForbesBenson, Don M.Peterman, SissyJohnson, David MichaelLi, DanielDansey, Roger D.Jahn, Thomas MichaelByrd, John C.
- [39] TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLCJOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S395 - S395Forster, M.Krebs, M.Majem, M.Peguero, J.Clay, T.Felip, E.Iams, W.Roxburgh, P.Doger, B.Bajaj, P.Kefas, J.Scott, J. A.Joaquin, A. BarbaMueller, C.Triebel, F.
- [40] A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent/metastatic head and neck cancer.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Brisson, Ryan J.Dekker, AllisonDe Souza, Jonas A.Saloura, VassilikiVokes, Everett E.Seiwert, Tanguy Y.